Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

Journal of Clinical Oncology

Volumn 18, Issue 20, 2000, Pages 3522-3528

  Friedman, Henry S ^a   Pluda, James ^a   Quinn, Jennifer A ^a   Ewesuedo, Reginald B ^a   Long, Lina ^a   Friedman, Allan H ^a   Cokgor, Ilkcan ^a   Calvin, O Michael ^a   Haglund, Michael M ^a   Ashley, David M ^a   Rich, Jeremy N ^a   Sampson, John ^a   Pegg, Anthony E ^a   Moschel, Robert C ^a   McLendon, Roger E ^a   Provenzale, James M ^a   Stewart, Elizabeth S ^a   Tourt Uhlig, Sandra ^a   Garcia Turner, Ana M ^a   Herndon II, James E ^a   Bigner, Darell D ^a   Dolan, M Eileen ^a   more..

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; CARMUSTINE; HYDROXYUREA; PROCARBAZINE; TAMOXIFEN; TEMOZOLOMIDE; TOPOTECAN; VINCRISTINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; GLIOBLASTOMA; HUMAN; MAXIMUM PERMISSIBLE DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0034668064     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.20.3522     Document Type: Article

References (49)

1. Chemotherapy of primary brain tumors
2. Therapy of adult malignant brain tumors: What have the clinical trials taught us?
3. The basis for current treatment recommendations for malignant gliomas
4. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas: A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study
5. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for treatment of malignant glioma
6. Pretreatment of human colon tumor cells with DNA methylating agents inhibits their activity to repair chloroethyl monoadducts
7. 6-alkylguanines
8. 6-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents
9. 6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents
10. 6-methylguanine DNA methyltransferase in cell survival, mutagenesis and carcinogenesis
11. 6-methylguanine as a free base
12. Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum (II) in human glial-derived lines
13. 6-alkylguanine-DNA alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea
14. 6-methylguanine
15. 6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain tumor xenografts
16. 6-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents
17. DNA alkylation by the haloethylnitrosoureas: Nature of modifications produced and their enzymatic repair or removal
18. 6-alkylguanine
19. Regulation of repair of alkylation damage in mammalian genomes
20. 6-alkylguanine-DNA alkyltransferase
21. 6-Alkylguanine-DNA alkyltransferase activity in human brain and brain tumors
22. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine
23. 6-Alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications
24. 6-methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma in patients treated with bis-chloroethylnitrosourea: A Southwest Oncology Group study
25. 6-alkylguanine-DNA alkyltransferase
26. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents
27. 6-benzylguanine and its effect on the sensitivity of human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea
28. 6-methylguanine
29. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents
30. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme
31. 6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation
32. 6-benzylguanine and 1,3 bis(2-chloroethyl)-1-nitrosourea
33. 6-benzylguanine
34. 6-Benzylguanine and its role in chemotherapy
35. 6-benzylguanine for patients undergoing surgery for malignant glioma
36. 6-benyzlguanine in humans: Metabolic, pharmacokinetic, and pharmacodynamic findings
37. Determination of 8-Oxoguanine in human plasma and urine by high-performance liquid chromatography with electrochemical detection
38. 6-alkylguanine-DNA alkyltransferase
39. 6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate
40. 6-benzylguanine
41. DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas
42. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs
43. Transcriptional activation of cytochrome P450 genes by different classes of chemical inducers
44. Preclinical approach for identifying drug interactions
45. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer
46. Pulmonary toxicity associated with bis-chloroethyl nitrosourea (BCNU)
47. 6-benzylguanine and temozolomide
48. 6-benzylguanine in the treatment of central nervous system tumor xenografts
49. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas